Edgewise Therapeutics
EWTX
48 hedge funds and large institutions have $796M invested in Edgewise Therapeutics in 2021 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 19 increasing their positions, 12 reducing their positions, and 2 closing their positions.
100% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 2
58% more repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 12
4% more funds holding
Funds holding: 46 → 48 (+2)
0.31% more ownership
Funds ownership: 97.21% → 97.52% (+0.31%)
23% less capital invested
Capital invested by funds: $1.03B → $796M (-$233M)
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$13.4M |
| 2 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$4.16M |
| 3 |
EC
EcoR1 Capital
San Francisco,
California
|
+$995K |
| 4 |
State Street
Boston,
Massachusetts
|
+$391K |
| 5 |
State of Wisconsin Investment Board
Madison,
Wisconsin
|
+$289K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LGM
Logos Global Management
San Francisco,
California
|
-$9.95M |
| 2 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$2.04M |
| 3 |
OCA
Octagon Capital Advisors
New York
|
-$1.36M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
-$1.08M |
| 5 |
Janus Henderson Group
London,
|
-$1.04M |
EWTX Hedge Fund Activity: Q3 2021 in Review
48 of the 5,728 institutional investors tracked by Wall St. Rank reported a position in Edgewise Therapeutics (EWTX) for Q3 2021, worth a combined $796M — down 23% from $1.03B a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new EWTX positions and 2 closed out — a net gain of 2 holders — while 19 added to existing stakes and 12 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $13.4M. The largest seller was Logos Global Management, cutting an estimated $9.95M.
- 48 institutional investors held Edgewise Therapeutics (EWTX) as of Q3 2021, up from 46 in Q2 2021.
- Funds reported $796M of Edgewise Therapeutics stock for Q3 2021, down 23% quarter-over-quarter.
- 4 funds opened new Edgewise Therapeutics positions in Q3 2021 and 2 closed out, a net change of +2 holders.
- The largest Edgewise Therapeutics buyer in Q3 2021 was Fidelity Investments, an estimated $13.4M added.
- The largest Edgewise Therapeutics seller in Q3 2021 was Logos Global Management, an estimated $9.95M sold.
Based on aggregated 13F filings for Q3 2021.